AKBA — structural market context
Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.
What changed
As of the close on Nov 4. Each line shows the earlier value, the later value and their dates.
Change from the Nov 3 close to the Nov 4 close: −4.28%.
1.34× its 20-session average on Nov 4.
Includes pre- and post-market trading.
Short interest 23.1M shares (settlement Oct 15) vs 22.5M (Sep 30).
No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.
Latest file (settlements Oct 1–Oct 14, published Nov 3): 9 days with fails, largest 95K shares on Oct 9.
Previous file (settlements Sep 15–Sep 30, published Oct 16): 12 days with fails, largest 152K shares on Sep 18.
None recorded in this window.
AKBA events and their magnitude
Latest SEC filing in the event study
8-K 3.01 · Listing compliance notice · filed 2026-10-23 · View on sec.gov ↗
…
AKBA short interest & days to cover
FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (21d ago)
AKBA fails-to-deliver (FTD)
SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.
AKBA analyst ratings
Rating actions as published by the firms, from public feeds. They are not graded here.
Frequently asked questions
Other companies in the same SEC industry: Pharmaceutical Preparations
Industry: SIC code 2834 as recorded on SEC EDGAR.
AKBA: the full history
Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.
Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.